Home

The Korea Herald

Latest news

Most Popular

  1. 1

    IMF lowers Korea's 2025 growth outlook to 2%

    IMF lowers Korea's 2025 growth outlook to 2%
  2. 2

    Labor Ministry dismisses Hanni harassment case

    Labor Ministry dismisses Hanni harassment case
  3. 3

    Reality show 'I Live Alone' disciplined for 'glorifying' alcohol consumption

    Reality show 'I Live Alone' disciplined for 'glorifying' alcohol consumption
  4. 4

    North Korean troops fighting alongside Russia, NIS confirms

    North Korean troops fighting alongside Russia, NIS confirms
  5. 5

    Japan to hold 1st memorial for Korean forced labor victims at Sado mine

    Japan to hold 1st memorial for Korean forced labor victims at Sado mine
  1. 6

    [Herald Interview] How Gopizza got big in India

    [Herald Interview] How Gopizza got big in India
  2. 7

    Yoon focuses on expanding global solidarity against NK-Russia military ties at APEC, G20 summits

    Yoon focuses on expanding global solidarity against NK-Russia military ties at APEC, G20 summits
  3. 8

    [KH Explains] Dissecting Hyundai Motor's lobbying in US

    [KH Explains] Dissecting Hyundai Motor's lobbying in US
  4. 9

    [Graphic News] 70% of S. Koreans believe couples can live together without tying the knot: survey

    [Graphic News] 70% of S. Koreans believe couples can live together without tying the knot: survey
  5. 10

    Now is no time to add pressure on businesses: top executives

    Now is no time to add pressure on businesses: top executives
지나쌤

Celltrion's Truxima hits Britain

By KH디지털2

Published : April 18, 2017 - 16:20

    • Link copied

South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that its biosimilar drug Truxima began selling in Britain following approval from a European regulator.

Starting earlier this month, Britain-based Napp Pharmaceuticals began distributing Celltrion's biosimilar to Roche's Mabthera at 50 hospitals in the country, Celltrion said.

(Yonhap) (Yonhap)

In February, the European Medicines Agency accepted Celltrion's application to sell the antibody biosimilar which is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin's lymphoma, a type of leukemia.

"The first administration of Truxima was completed following the official launch," said a Celltrion official not to be named.

With EMA approval, the biosimilar can also be sold in 28 European Union countries, as well as Norway, Iceland and Lichtenstein, company officials said.

Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)

More from Headlines